Share this

One-third of the world’s population is currently infected with the tuberculosis (TB) bacillus. Every year, nine million people develop active TB and 1.5 million die from it.

TB is spread through the air when infected people cough or sneeze. Not everyone infected with TB becomes ill, but 10 per cent
will develop active TB at some point in their lives. The disease most often affects the lungs. Symptoms include a persistent cough, fever, weight loss, chest pain and breathlessness in the lead-up to death. TB incidence is much higher and is a leading cause of death among people with HIV.

Diagnosis of TB depends on a phlegm sample, which can be difficult to obtain from children. There is a new molecular test that can give results after just two hours, and detect a certain level of drug resistance, but it is costly, depends on a reliable power supply, and still requires a phlegm sample.

A course of treatment for uncomplicated TB takes a minimum of six months. When patients are resistant to the two most powerful first-line antibiotics, they are considered to have multidrug-resistant TB (MDR-TB). MDR-TB is not impossible to treat, but the drug regime is arduous, taking up to two years and causing many side effects. Extensively drug-resistant tuberculosis (XDR-TB) is identified when resistance to second-line drugs develops on top of MDR-TB. The treatment options for XDR-TB are limited.

Press release
Examining the experiences of patients and staff involved in the ‘TB & ME’ blogging project
Medical publications
Nevirapine and efavirenz exposure on and off TB treatment and consequences for efficacy and...
MSF runs the only hospital in the area, providing comprehensive services including HIV & TB...
Medical publications
Management of MDR-TB patients co-infected with HIV is highly challenging. A mental health...
Arif Uddin Kazi was born near the Sundarbans, a mangrove forest almost the size of the small...
Ukraine: Effects of conflict spreading whilst health system struggles to cope
Medical publications
Patch-testing for the management of hypersensitivity reactions to second-line anti-tuberculosis...
Home visits are a key part of the recovery from illness
Does the Global Fund’s New Funding Model foster country ambitions?
Medical publications
Impact of Introducing the Line Probe Assay on Time to Treatment Initiation of MDR-TB in Delhi, India
Khanyi describes her delight at being cured of TB
MSF's nurse manager describes the challenges in tackling TB
Linezolid Fact Sheet
Press release
South African authorities allow importation of successful drug to combat TB
A Year in Focus 2013-2014
An interview with Elias Pavlopoulos, outgoing Head of Mission for MSF in Swaziland